Article Per Year (5 Year)
p-Index From 2019 - 2024
0.61
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran JIMKI : Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
Abiyyu Didar Haq
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Antibodi Monoklonal Anti-CD3 Sebagai Terapi Diabetes Mellitus Tipe 1: Sebuah Kajian Sistematis dan Meta-analisis Visakha Vidyadevi Wiguna; Abiyyu Didar Haq; Luh Ade Dita Rahayu
Unram Medical Journal Vol 10 No 3 (2021): Jurnal Kedokteran volume 10 nomor 3 2021
Publisher : Faculty of Medicine Universitas Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/jku.v10i3.580

Abstract

Introduction: Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease which marked by a persistent increase in blood glucose (hyperglycemia). T1DM is thought to be caused by an autoreactivity of T cell which mediates the apoptosis of insulin-producing cells in the pancreas. Those mechanism causes a life-long dependance on exogen insulin. Current immunotherapy strategy is inhibiting or deleting the lymphocyte subset and/or through the use of agents which will induce the tolerance by activating regulatory T cell such as the use of anti-CD3. Therapy using monoclonal antibody also has a continous effect as compared to immunosupressive agents that traditionally being used.Methods: A systematic review was conducted based on PRISMA through PubMed, ScienceDirect, Directory of Open Access Journal, Wiley, Cochrane Library, Google Scholar, and Scopus, searching for randomized controlled trials which analyze anti-CD3’s effects on clinical outcomes of T1DM patients. Studies selected were then assessed for bias risk with CONSORT criteria. Random-effects meta-analysis was performed to estimate the pooled mean difference (MD) along with their 95% confidence intervals (CIs).Results: The search yielded ten RCTs with a total of 1,458 subjects. Anti-CD3 intervention is proven to be effective in reducing insulin’s usage (MD -0,18 [95% CI: -0.22, -0.13],I2=59%, p<0,0001) and HbA1C (MD -0.71[95% CI: -1.18, -0.24], I2=78%, p=0.003) significantly. Furthermore, there is another clinical benefits, such as reducing the decrease of C-peptide response significantly. Conclusion: To conclude, anti CD-3 showed promising results to be widely implemented as treatment for T1DM patients.
POTENSI PITAVASTATIN DENGAN NANOPARTIKEL POLY(DL-LACTIDE-CO-GLYCOLIDE) (PLGA) DRUG DELIVERY SYSTEM SEBAGAI TERAPI ADJUVAN PADA PENYAKIT JANTUNG KORONER Visakha Vidyadevi Wiguna; Abiyyu Didar Haq; Luh Gde Sri Adnyani Suari
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol 9 No 3 (2022): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 9.3 Edisi Desember 202
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.v9i3.453

Abstract

ABSTRACT Background: During COVID-19 pandemic, people’s mobility is decreased. This phenomenon leads to the increase of sedentary lifestyle hence increasing the risk of cardiometabolic diseases. One of the disease that has a strong connection with sedentary lifestyle is Coronary Artery Disease (CAD). CAD is the most common cardiovascular disease that causes death contributing as much as 12% of all death in the world. Percutaneous coronary intervention (PCI) therapy in the acute phase of myocardial infarct can lower the infarct area but the risk of ischemic-reperfusion injury limits its therapeutic effect. Methods: This literature review uses journal articles that are sourced from online databases such as PubMed and Google Scholar. The literature search utilized several keywords such as “pitavastatin”, “drug delivery system”, “nanoparticle”, “PLGA”, “myocardial infarction”, “ischemic-reperfusion injury”. The search yielded 34 relevant literatures which used in this literature review Discussion: Pitavastatin is a statin which possesses a significant effect on LDL-C, TG, and HDL-C. Furthermore, pitavastatin also possess cardioprotective effect on ischemic-reperfusion injury by decreasing oxidative stress and increasing intracellular antioxidant. PLGA nanoparticle is proven to increase the therapeutic effect of pitavastatin because of its ability to deliver timely and its anti-inflammatory effect. . Conclusion: Pitavastatin encapsulated by PLGA nanoparticle has the ability to prevent ischemic-reperfusion injury. Current therapeutic strategy has not been able to deliver pitavastatin into the infarct site adequately in the timely manner hence PLGA needed as drug delivery system.
Faktor – Faktor Terkait Tingkat Keparahan Infeksi Coronavirus Disease 2019 (COVID-19): Sebuah Kajian Literatur Abiyyu Didar Haq; Adli Putra Nugraha; I Komang Gede Andhika Wibisana; Febbi Anggy; Fiana Damayanti; R.R. Ditya Mutiara Syifa; Ni Putu Visty Widhiani; Cut Warnaini
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol 9 No 1 (2021): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 9.1 Edisi Maret - Juli
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.v9i1.338

Abstract

Background: COVID-19 pandemic that started in the early 2020 triggers the declaration of Public Health Emergency of International Concern (PHEIC) by WHO. Caused by SARS-CoV-2 virus, COVID-19 mainly infects the respiratory tract by binding to the ACE2 receptor. COVID-19 infection can cause many clinical manifestation from no symptom to severe life-threatening symptom depending on many factors. Factors that can determine the severity of clinical manifestation is urgently needed to be recognized by our clinician in order to be able to anticipate patient’s condition before the severe clinical manifestation even begins. This literature review is aimed to summarize and discuss some factors that are most often showed up and determined the severity of COVID-19 infection. Methods: This literature review uses journal article that are sourced from online databases such as PubMed and Google Scholar. The type of article that will be chosen are research article, systematic review and meta-analysis, narrative review, and literature review with the topic of transmission, clinical manifestasion, pathogenesis, immune response, and severity risk factor of COVID-19. Discussion: From our literature search, it is concluded that the factors that are most likely to determine the severity of COVID-19 infection is age, comorbid disease, vitamin D deficiency, and obesity. These four factors are not four independent factors but rather overlapping and interconnecting factors that determines the severity of COVID-19 infection. Conclusion: Most of the factors that determined the severity of COVID-19 mainly are easily preventable factors. Therefore, the knowledge and awareness of our clinician about these factors will really helps anticipating the severe clinical manifestation among COVID-19 patients before the manifestation even starts to appear.
Co-Authors Adli Putra Nugraha Cut Warnaini Febbi Anggy Fiana Damayanti I Komang Gede Andhika Wibisana Luh Ade Dita Rahayu Luh Gde Sri Adnyani Suari Ni Putu Visty Widhiani R.R. Ditya Mutiara Syifa Visakha Vidyadevi Wiguna Visakha Vidyadevi Wiguna